{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:03:55Z","timestamp":1788264235271,"version":"build-2803163510"},"reference-count":0,"publisher":"Managed Care and Healthcare Communications, LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Manag Care"],"DOI":"10.37765\/ajmc.2020.42400","type":"journal-article","created":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T09:55:04Z","timestamp":1582797304000},"page":"e41-e49","source":"Crossref","is-referenced-by-count":10,"title":["Cost-effectiveness of brentuximab vedotin with chemotherapy in treatment of CD30-expressing PTCL"],"prefix":"10.37765","volume":"26","member":"24492","published-online":{"date-parts":[[2020,2,11]]},"container-title":["The American Journal of Managed Care"],"original-title":[],"language":"en","deposited":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T09:55:05Z","timestamp":1582797305000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajmc.com\/journals\/issue\/2020\/2020-vol26-n2\/costeffectiveness-of-brentuximab-vedotin-with-chemotherapy-in-treatment-of-cd30expressing-ptcl"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,11]]},"references-count":0,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2,1]]},"published-print":{"date-parts":[[2020,2,1]]}},"URL":"https:\/\/doi.org\/10.37765\/ajmc.2020.42400","archive":["Portico","Portico"],"relation":{},"ISSN":["1936-2692","1088-0224"],"issn-type":[{"value":"1936-2692","type":"electronic"},{"value":"1088-0224","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2,11]]}}}